As of May 2021, U.S. investor Blackrock Inc owned more than ***** percent of total shares of pharmaceutical companies AstraZeneca, Pfizer, Novavax, and Johnson & Johnson, respectively. The statistic illustrates major shareholdings at select pharmaceutical companies which are involved in the development and production of COVID-19 vaccines as of May 2021, by investor.

Content

Stock data of the following companies from Oct 2019 is included in this dataset. (BioNTech , Moderna , Johnson & Johnson , Inovio Pharmaceuticals, Sinovac , Sinopharm , Novavax ,Astrazeneca(Oxford)) (The date 2019 was chosen because few companies got IPO just in 2019)

Inspiration

To do more analysis on the performance of the companies with the influence of covid vaccine.

End note

Please let me know if any more companies are to be included or any changes have to be made to improve the quality of the dataset in the discussion section.

As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

Market Overview: The global COVID-19 inactivated vaccine market is projected to reach a substantial market size by 2033, exhibiting a promising Compound Annual Growth Rate (CAGR) during the forecast period (2025-2033). This growth is attributed to the ongoing COVID-19 pandemic, the need for effective vaccines, and rising vaccination rates. Key drivers of the market include increasing government initiatives to control the spread of COVID-19, rising healthcare awareness, and advancements in vaccine technology. However, factors such as vaccine hesitancy and supply chain disruptions pose challenges to market growth. Competitive Landscape and Regional Analysis: The COVID-19 inactivated vaccine market is highly competitive, with several leading players holding significant shares. Key companies operating in the market include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, and ExpreS2ion Biotechnologies ApS. Regionally, North America and Europe are expected to dominate the market due to high vaccination rates and government support. Emerging markets such as Asia-Pacific and Latin America present significant growth potential due to increasing healthcare spending and vaccination efforts.

Covid-19 Vaccine Logistics Market Outlook

The global Covid-19 Vaccine Logistics market size was valued at approximately USD 12.5 billion in 2023 and is projected to reach USD 18.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period. The growth of the market is primarily driven by the urgent global need for effective and efficient distribution of Covid-19 vaccines, along with the continuous advancements in logistics technology and infrastructure.

One of the primary growth factors driving the Covid-19 Vaccine Logistics market is the unprecedented global demand for Covid-19 vaccines. The pandemic has highlighted the critical need for rapid and reliable vaccine distribution to curb the spread of the virus and achieve herd immunity. Governments and healthcare organizations are investing heavily in logistics to ensure that vaccines are delivered safely and efficiently to all corners of the world. Additionally, the development of multiple vaccine types, each with specific storage and handling requirements, has further fueled the need for specialized logistics services.

Another significant factor contributing to the market's growth is the technological advancements in the logistics sector. Innovations such as temperature-controlled packaging, real-time tracking systems, and advanced cold chain solutions have revolutionized the way vaccines are transported and stored. These technologies ensure that vaccines remain effective throughout the distribution process, reducing the risk of spoilage and wastage. The integration of Internet of Things (IoT) devices and blockchain technology in vaccine logistics has also improved transparency and traceability, enhancing the overall efficiency and reliability of the supply chain.

The increasing collaboration between public and private sectors is also a key driver of market growth. Governments, pharmaceutical companies, and logistics providers are working together to develop robust distribution networks and overcome logistical challenges. Public-private partnerships (PPPs) have facilitated the sharing of resources, expertise, and infrastructure, leading to more effective vaccine distribution strategies. Additionally, financial support from international organizations and initiatives such as COVAX has played a crucial role in ensuring equitable access to vaccines, particularly in low- and middle-income countries.

From a regional perspective, North America and Europe have been at the forefront of Covid-19 vaccine logistics due to their advanced healthcare infrastructure and strong logistics capabilities. However, significant growth opportunities exist in the Asia Pacific and Latin America regions, driven by the large population base and increasing government initiatives to improve healthcare access. The Middle East & Africa region also presents potential growth opportunities, albeit at a slower pace, due to ongoing efforts to enhance their logistics networks and healthcare infrastructure.

Service Type Analysis

In the Covid-19 Vaccine Logistics market, the service types are categorized into transportation, warehousing, packaging, and others. Each of these services plays a crucial role in ensuring the timely and safe delivery of vaccines.

Transportation services are the backbone of vaccine logistics, involving the movement of vaccines from manufacturing facilities to distribution centers and, ultimately, to vaccination sites. This segment is critical due to the need for specialized vehicles equipped with temperature-controlled systems to maintain the integrity of vaccines. Air transport has been particularly significant for long-distance and international shipments, offering speed and reliability. Road transport, on the other hand, is essential for last-mile delivery, ensuring vaccines reach even the most remote areas.

Warehousing services are another vital component of vaccine logistics. Proper storage facilities are necessary to maintain the required temperature conditions for vaccines. Cold storage warehouses equipped with advanced refrigeration systems ensure that vaccines remain effective until they are dispatched for distribution. The demand for warehousing services has surged, leading to investments in expanding existing facilities and constructing new ones to handle the increased volume of vaccines.

Packaging services in vaccine logistics involve the use of specialized materials and techniques to protect vaccines during transit. Temperature-sensitive packaging solutions, such as insulated contai

The global market for Novel Coronavirus Inactivated Vaccines experienced significant growth driven by the COVID-19 pandemic. While precise market size data for 2019-2024 isn't provided, we can infer substantial expansion based on the widespread vaccine rollout. Let's assume a conservative 2024 market size of $15 billion, considering the immense global vaccination campaigns. Assuming a Compound Annual Growth Rate (CAGR) of 10% (a figure reflecting both continued demand for booster shots and potential new variants requiring updated vaccines), the market is projected to reach approximately $25 billion by 2025 and continue to grow steadily. This growth is fueled by ongoing vaccination efforts, particularly in developing nations with lower vaccination rates, and the potential for future pandemics. Factors such as government initiatives supporting vaccine development and distribution, along with the evolving understanding of COVID-19 and its long-term effects, are key drivers. However, market growth will likely moderate in the coming years as initial pandemic-related urgency subsides. Factors like waning immunity, the emergence of new variants, and the potential for alternative prophylactic measures will influence the long-term trajectory. The market is segmented by type (adult and child formulations) and application (hospitals and clinics). Leading companies involved in the production and distribution of these vaccines include Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson & Johnson, and several prominent Chinese pharmaceutical companies. The Asia-Pacific region, particularly China and India, is expected to exhibit significant growth, driven by their large populations and increasing healthcare infrastructure. The forecast period of 2025-2033 presents opportunities and challenges. While the initial surge in demand is likely to slow, consistent demand for booster shots and potential new vaccine formulations adapted to emerging variants will sustain market growth. The continued development of more effective and convenient vaccine delivery methods, coupled with global health initiatives aiming to improve vaccination access in underserved communities, will be critical factors influencing the market trajectory. Competition among pharmaceutical companies will remain intense, necessitating innovation and strategic partnerships. Regulatory approvals and safety concerns will also play pivotal roles in shaping market dynamics throughout the forecast period. By 2033, a more mature market is anticipated, with a focus on innovation, long-term preventative strategies, and sustainable growth.

To facilitate effective targeted COVID-19 vaccination strategies, it is important to understand reasons for vaccine hesitancy where uptake is low. Artificial intelligence (AI) techniques offer an opportunity for real-time analysis of public attitudes, sentiments, and key discussion topics from sources of soft-intelligence, including social media data. In this work, we explore the value of soft-intelligence, leveraged using AI, as an evidence source to support public health research. As a case study, we deployed a natural language processing (NLP) platform to rapidly identify and analyse key barriers to vaccine uptake from a collection of geo-located tweets from London, UK. We developed a search strategy to capture COVID-19 vaccine related tweets, identifying 91,473 tweets between 30 November 2020 and 15 August 2021. The platform's algorithm clustered tweets according to their topic and sentiment, from which we extracted 913 tweets from the top 12 negative sentiment topic clusters. These tweets were extracted for further qualitative analysis. We identified safety concerns; mistrust of government and pharmaceutical companies; and accessibility issues as key barriers limiting vaccine uptake. Our analysis also revealed widespread sharing of vaccine misinformation amongst Twitter users. This study further demonstrates that there is promising utility for using off-the-shelf NLP tools to leverage insights from social media data to support public health research. Future work to examine where this type of work might be integrated as part of a mixed-methods research approach to support local and national decision making is suggested.

The coronavirus pandemic has affected the entire world and many families have been destroyed. The stock exchange was also affected, but vaccine companies took advantage of this moment and leveraged their profits

Biotech companies:

• PFIZER: Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas.

• ASTRAZENECA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• BIONTECH: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

• MODERNA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• NOVAVAX: Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.

Check the movement of the financial market through this dataset

Use your creativity and external information

The global COVID-19 Vaccine Transportation market is projected to grow from XXX million in 2025 to XXX million by 2033, at a CAGR of 5% during the forecast period. The market is driven by the increasing need for efficient and effective transportation of COVID-19 vaccines due to their sensitive nature and the need to maintain their integrity during transportation. Refrigerated storage and cold chain logistics play a crucial role in ensuring the stability and efficacy of vaccines. Key trends in the market include the increasing adoption of advanced technologies such as temperature-controlled packaging and GPS tracking systems to monitor vaccine shipments and ensure their safety. The market is also expected to benefit from the growing investment in healthcare infrastructure and the expansion of vaccination programs globally. However, factors such as the high cost of transportation and the need for specialized logistics providers may restrain market growth. Regional variations in vaccine distribution policies and regulations can also impact the market's growth. Major companies operating in the market include DHL, FedEx, UPS, TNT Post Group, Nippon Express, S.F. Express, Hiron, Zhejiang Int'l Group, China National Accord, Square Technology Group, and Aucma.

Given that vaccine-induced adverse effects were mostly based on previous laboratory research and clinical trials, real-world data on the safety of coronavirus disease 2019 (COVID-19) vaccination were lacking. This study reported the adverse events (AEs) among inactivated COVID-19 vaccine recipients. Data were collected from a total of 2,808 hospital employees and their family members in Wuhan, China, with all of them receiving the first dose of inactivated COVID-19 vaccines from two pharmaceutical companies. The first dose was given between 29th April and 13th May 2021. A total of 2,732 vaccinees received the second dose between 27th May and 8th July 2021. The whole process of receiving the vaccine was monitored by clinical pharmacists, and the information on AEs including demographics, occurrence, types, and severity was recorded through an online questionnaire and telephone follow-up. Most of the common AEs were mild and tolerable, and the overall incidence of AEs was lower than the data from the safety profile in clinical trials. Moreover, the incidence of AEs in the first dose (21.30%, 598) was higher than that in the second dose (16.07%, 439). Furthermore, the first injection had more severe AEs (4, 0.14%) than the second injection (2, 0.07%). The AEs involved the skin, muscle, respiratory tract, gastrointestinal tract, cardiovascular system, and other tissues and systems. The most common AE was pain at the injection site (first dose: 10.19%, second dose: 12.55%). All the vaccinees with AEs for both doses recovered fully in the end. It was noted that some AEs might cause blood coagulation disorder and bleeding risk. Therefore, ongoing monitoring of AEs after COVID-19 vaccination is essential in evaluating the benefits and risks of each vaccine.

Context

The research shows that the U.S. had secured 1.01 billion doses from six different companies up to November 20 which represents the highest quantity of any government apart from India which has made agreements for 1.6 billion. Pfizer/BioNTech and Moderna both account for 100 million U.S. doses each while the U.S. is also set for 500 million doses of the vaccine being developed by the University of Oxford and AstraZeneca.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Content

This chart shows the number of doses of Covid-19 vaccines secured by the U.S. as of November 20, 2020.

Acknowledgements

Niall McCarthy, Data Journalist.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Inspiration

Covid-19 Pandemic.

The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.

Association of educational level and social-economic status with reluctance towards coronavirus disease vaccination and motivations for participation in vaccination among the general population of Shiraz.

BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings.MethodsWe performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information.ResultsSignificant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR).ConclusionsThe study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines.

About Dataset: WHO COVID-19 Global Data

This dataset provides comprehensive information on the global COVID-19 pandemic as reported to the World Health Organization (WHO). The dataset is available in comma-separated values (CSV) format and includes the following fields:

Daily cases and deaths by date reported to WHO: WHO-COVID-19-global-data.csv

• Date_reported (Date): The date of reporting to WHO.
• Country_code (String): The ISO Alpha-2 country code.
• Country (String): The name of the country, territory, or area.
• WHO_region (String): The WHO regional office to which the country belongs. WHO Member States are grouped into six WHO regions, including AFRO (Regional Office for Africa), AMRO (Regional Office for the Americas), SEARO (Regional Office for South-East Asia), EURO (Regional Office for Europe), EMRO (Regional Office for the Eastern Mediterranean), and WPRO (Regional Office for the Western Pacific).
• New_cases (Integer): The number of new confirmed cases reported on a given day. This is calculated by subtracting the previous cumulative case count from the current cumulative case count.
• Cumulative_cases (Integer): The total cumulative confirmed cases reported to WHO up to the specified date.
• New_deaths (Integer): The number of new confirmed deaths reported on a given day. Similar to new cases, this is calculated by subtracting the previous cumulative death count from the current cumulative death count.- Cumulative_deaths (Integer): The total cumulative confirmed deaths reported to WHO up to the specified date.

In addition to the COVID-19 case and death data, this dataset also includes valuable information related to COVID-19 vaccinations. The vaccination data consists of the following fields:

Vaccination Data Fields: vaccination-data.csv

• COUNTRY (String): Country, territory, or area.
• ISO3 (String): ISO Alpha-3 country code.
• WHO_REGION (String): The WHO regional office to which the country belongs.
• DATA_SOURCE (String): Indicates the data source, which can be either "REPORTING" (Data reported by Member States or sourced from official reports) or "OWID" (Data sourced from Our World in Data COVID-19 Vaccinations).
• DATE_UPDATED (Date): Date of the last update.
• TOTAL_VACCINATIONS (Integer): Cumulative total vaccine doses administered.
• PERSONS_VACCINATED_1PLUS_DOSE (Decimal): Cumulative number of persons vaccinated with at least one dose.
• TOTAL_VACCINATIONS_PER100 (Integer): Cumulative total vaccine doses administered per 100 population.
• PERSONS_VACCINATED_1PLUS_DOSE_PER100 (Decimal): Cumulative persons vaccinated with at least one dose per 100 population.
• PERSONS_LAST_DOSE (Integer): Cumulative number of persons vaccinated with a complete primary series.
• PERSONS_LAST_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with a complete primary series per 100 population.
• VACCINES_USED (String): Combined short name of the vaccine in the format "Company - Product name."
• FIRST_VACCINE_DATE (Date): Date of the first vaccinations, equivalent to the start/launch date of the first vaccine administered in a country.
• NUMBER_VACCINES_TYPES_USED (Integer): Number of vaccine types used per country, territory, or area.
• PERSONS_BOOSTER_ADD_DOSE (Integer): Cumulative number of persons vaccinated with at least one booster or additional dose.
• PERSONS_BOOSTER_ADD_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with at least one booster or additional dose per 100 population.

In addition to the vaccination data, a separate dataset containing vaccination metadata is available, including information about vaccine names, product names, company names, authorization dates, start and end dates of vaccine rollout, and more.

Vaccination metadata Fields: vaccination-metadata.csv

• ISO3 (String): ISO Alpha-3 country code
• VACCINE_NAME (String): Combined short name of vaccine: "Company - Product name" (see below)
• PRODUCT_NAME (String): Name or label of vaccine product, or type of vaccine (if unnamed).
• COMPANY_NAME (String): Marketing authorization holder of vaccine product.
• FIRST_VACCINE_DATE (Date): Date of first vaccinations. Equivalent to start/launch date of the first vaccine administered in a country.
• AUTHORIZATION_DATE (Date): Date vaccine product was authorized for use in the country, territory, area.
• START_DATE (Date): Start/launch date of vaccination with vaccine type (excludes vaccinations during clinical trials).
• END_DATE (Date): End date of vaccine rollout
• COMMENT (String): Comments related to vaccine rollout
• DATA_SOURCE (String): Indicates data source - REPORTING: Data reported by Member States, or sourced from official re...

Content

The data presented in the Vaccine Tracker are submitted by European Union/European Economic Area (EU/EEA) countries to ECDC through The European Surveillance System (TESSy) twice a week (Tuesdays and Fridays). EU/EEA countries report aggregated data on the number of vaccine doses distributed by manufacturers to the country, the number of first, second and unspecified doses administered in the adult population (18+) overall, by age group and in specific target groups, such as healthcare workers (HCW) and in residents in long-term care facilities (LTCF). Doses are also reported by vaccine product. The downloadable data files contain the data on the COVID-19 vaccine rollout mentioned above and each row contains the corresponding data for a certain week and country. The file is updated daily. Data are subject to retrospective corrections; corrected datasets are released as soon as processing of updated national data has been completed. You may use the data in line with ECDC’s copyright policy.

• YearWeekISO: Date when the vaccine was received/administered. Only weeks are allowed (e.g. “2021-W01”). [yyyy-Www]
• ReportingCountry: ISO 3166-1-alpha-2 two-letter code
• Denominator: Population denominators for target groups (total population and agespecific population denominators do not need to be reported and will be obtained from Eurostat/UN). Denominators only need to be reported for TargetGroup = “HCW” and TargetGroup = “LTCF”. They should be reported every week for these target groups. [Numeric]
• NumberDosesReceived: Number of vaccine doses distributed by the manufacturers to the country during the reporting week. [Numeric]
• FirstDose: Number of first dose vaccine administered to individuals during the reporting week. [Numeric]
• FirstDoseRefused: Number of individuals refusing the first vaccine dose.[Numeric]
• SecondDose: Number of second dose vaccine administered to individuals during the reporting week.[Numeric]
• UnknownDose: Number of doses administered during the reporting week where the type of dose was not specified (i.e. it is not known whether it was a first or second dose).[Numeric]
• Region: As a minimum data should be reported at national level (Region = country code). Country/NUTS1 or 2/GAUL1/Country specific

• TargetGroup: Target group for vaccination. As a minimum the following should be reported: “ALL” for the overall figures, “HCW” for healthcare workers and age-groups (preferably using the detailed age-groups) ALL = Overall HCW = Healthcare workers LTCF = Residents in long term care facilities Age18_24 = 18-24 year-olds Age25_49 = 25-49 year-olds Age50_59 = 50-59 year-olds Age60_69 = 60-69 year-olds Age70_79 = 70-79 year-olds Age80+ = 80 years and over AgeUnk = Unknown age 1_Age<60 = below 60 years of age 1_Age60+ = 60 years and over

• Vaccine: Name of vaccine. Additional vaccines will be added on approval or as requested. COM = Comirnaty – Pfizer/BioNTech MOD = mRNA-1273 – Moderna CN = BBIBV-CorV – CNBG SIN = Coronavac – Sinovac SPU = Sputnik V - Gamaleya Research Institute AZ = AZD1222 – AstraZeneca UNK = UNKNOWN

• Population: Age-specific population for the country [Numeric]

##

Acknowledgements

European Centre for Disease Prevention and Control

Association of age and gender with reluctancy towards coronavirus disease vaccination and the motivation to participate in vaccination among the general population of Shiraz.

Vaccine Adjuvant Market Outlook

According to our latest research, the global vaccine adjuvant market size stood at USD 1.35 billion in 2024, and it is projected to grow at a robust CAGR of 8.7% from 2025 to 2033. By the end of 2033, the market is expected to reach approximately USD 2.85 billion. The surge in demand for more effective and long-lasting vaccines, coupled with continued investments in immunization programs and biotechnology advancements, is a significant growth factor shaping the vaccine adjuvant industry worldwide.

One of the primary growth drivers for the vaccine adjuvant market is the increasing prevalence of infectious diseases and emerging pandemics, which has heightened the need for advanced vaccine formulations. Vaccine adjuvants play a crucial role in enhancing the immune response, allowing for lower antigen doses and improved efficacy, which is particularly important in pandemic scenarios where rapid mass immunization is required. The COVID-19 pandemic, for instance, underscored the vital importance of adjuvants in accelerating vaccine development and deployment. Additionally, the growing geriatric population, which is more susceptible to infectious diseases due to age-related immune decline, has further fueled the demand for potent adjuvant-containing vaccines. This demographic shift is expected to sustain market growth over the forecast period as healthcare systems prioritize immunization for vulnerable populations.

Another significant factor propelling the vaccine adjuvant market is the ongoing research and development activities in the field of immunology and vaccinology. Pharmaceutical companies and research institutes are investing heavily in the discovery of novel adjuvant molecules that offer improved safety profiles and tailored immune responses. The integration of innovative adjuvant technologies, such as saponin-based and liposome adjuvants, is expanding the scope of vaccines for both infectious and non-infectious diseases, including cancer and allergies. The increased focus on personalized medicine and the development of therapeutic vaccines are also creating new avenues for adjuvant application, thereby broadening the market landscape. Furthermore, regulatory agencies are providing clear guidelines and support for the approval of adjuvanted vaccines, which is streamlining product development and commercialization processes.

The vaccine adjuvant market is also being shaped by growing public and private sector collaborations aimed at enhancing global immunization coverage. Governments and international organizations, such as the World Health Organization and Gavi, the Vaccine Alliance, are actively supporting vaccination campaigns in developing regions, which is driving the adoption of adjuvant-containing vaccines. In addition, partnerships between biotechnology firms and large pharmaceutical companies are accelerating the translation of research findings into commercial products. The increasing awareness among healthcare professionals and the general public about the benefits of adjuvanted vaccines is contributing to higher vaccination rates and market expansion. However, challenges related to adjuvant safety and regulatory complexities persist, necessitating continuous innovation and vigilance in product development.

The exploration of CpG Oligonucleotide Adjuvants is gaining traction in the field of vaccine development due to their ability to enhance both innate and adaptive immune responses. These adjuvants work by mimicking the natural immune-stimulating properties of bacterial DNA, thereby activating toll-like receptor 9 (TLR9) pathways. This mechanism is particularly beneficial in vaccines targeting viral infections and cancers, where a strong immune response is crucial. The integration of CpG Oligonucleotide Adjuvants into vaccine formulations is being actively researched, with promising results in preclinical and clinical trials. Their potential to improve vaccine efficacy and reduce the required antigen dose makes them an attractive option for next-generation vaccines. As research progresses, these adjuvants may play a pivotal role in addressing the challenges of emerging infectious diseases and enhancing the effectiveness of therapeutic vaccines.

Regionally, North America continues to dominate the vaccine adjuvant market, supported by advanced healthcare infrastructure,